

## Akcea Therapeutics to Present at 15th Annual Needham Healthcare Conference

April 6, 2016 7:01 AM ET

CAMBRIDGE, Mass., April 6, 2016 /PRNewswire/ -- Akcea Therapeutics, a subsidiary of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) focused on developing and commercializing new treatments for serious cardiometabolic diseases, today announced that management will present a company overview at the 15<sup>th</sup> Annual Needham Healthcare Conference at 4:40 p.m. ET on Tuesday, April 12, 2016 in New York, NY.



---

*A subsidiary of Ionis Pharmaceuticals, Inc.*

A live webcast of the presentation will be available on the "Investors & Media" section of the Ionis website. The replay will be available within 48 hours and will be archived for a limited time.

### **ABOUT AKCEA THERAPEUTICS**

Akcea Therapeutics is a development and commercialization company focused on transforming the lives of patients with serious cardiometabolic lipid disorders. Established as a wholly-owned subsidiary of Ionis Pharmaceuticals, Inc., Akcea has a robust portfolio of development-stage drugs covering multiple targets and disease states using advanced RNA-targeted antisense therapeutics. Akcea's drug pipeline includes novel antisense drugs designed to address a number of lipid risk factors, including LDL-cholesterol, ApoC-III, triglycerides and Lp(a). Akcea's most advanced program, volanesorsen, is in Phase 3 development to treat patients with either familial chylomicronemia syndrome (FCS) or familial partial lipodystrophy (FPL), two ultra-orphan lipid disorders that are characterized by extremely high triglycerides and ApoC-III. Akcea is located in Cambridge, Massachusetts. Additional information about Akcea is available at [www.akceatx.com](http://www.akceatx.com).

### **ABOUT IONIS PHARMACEUTICALS, INC.**

Ionis is the leading company in RNA-targeted drug discovery and development focused on developing drugs for patients who have the highest unmet medical needs, such as those patients with severe and rare diseases. Using its proprietary antisense technology, Ionis has created a large pipeline of first-in-class or best-in-class drugs, with over a dozen drugs in mid- to late-stage development. Drugs currently in Phase 3 development include volanesorsen, a drug Ionis is developing and plans to commercialize through its wholly owned subsidiary, Akcea Therapeutics, to treat patients with either familial chylomicronemia syndrome or familial partial lipodystrophy; IONIS-TTR<sub>RX</sub>, a drug Ionis is developing with GSK to treat patients with all forms of TTR amyloidosis; and nusinersen, a drug Ionis is developing with Biogen to treat infants and children with spinal muscular atrophy. Ionis' patents provide strong and extensive protection for its drugs and technology. Additional information about Ionis is available at [www.ionispharma.com](http://www.ionispharma.com).

### **FORWARD-LOOKING STATEMENT**

This press release includes forward-looking statements regarding Ionis Pharmaceuticals Inc. and its wholly owned subsidiary, Akcea Therapeutics, Inc. Any statement describing Ionis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. Ionis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements.

Although Ionis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Ionis. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Ionis' programs are described in additional detail in Ionis' annual report on Form 10-K for the year ended December 31, 2015, which is on file with the SEC. Copies of this and other documents are available from the Company.

In this press release, unless the context requires otherwise, "Ionis," "Company," "we," "our," and "us" refers to Ionis Pharmaceuticals and its subsidiaries.

Ionis Pharmaceuticals™ is a trademark of Ionis Pharmaceuticals, Inc. Akcea Therapeutics™ is a trademark of Ionis Pharmaceuticals, Inc.



Logo - <http://photos.prnewswire.com/prnh/20160118/323100LOGO>

Logo - <http://photos.prnewswire.com/prnh/20151221/317736LOGO>

To view the original version on PR Newswire, visit: <http://www.prnewswire.com/news-releases/akcea-therapeutics-to-present-at-15th-annual-needham-healthcare-conference-300246614.html>

SOURCE Ionis Pharmaceuticals, Inc.; Akcea Therapeutics

D. Wade Walke, Ph.D., Vice President, Corporate Communications and Investor Relations, 760-603-2741, OR Amy Williford, Ph.D., Associate Director, Corporate Communications, 760-603-2772